🔗 Permalink

Inventor profile of:

Ety Klinger

City:

Tel Aviv

Country:

Israel

Published Applications:

Last publication date:

2019-06-13

Top Assignees for applications by Ety Klinger

The entities that hold a legal rights for patent applications filed by inventor Klinger Ety:

Teva Pharmaceutical Industries, Ltd. 7 Petach-Tikva, Israel
Yeda Research Development Co. Ltd. 5 Rehovot, Israel

Recent patent applications by Klinger Ety

Ety Klinger from Tel Aviv, IL has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2019-06-13

US20190175494A1

Human necessities

LOW FREQUENCY GLATIRAMER ACETATE THERAPY

#2 | 2019-02-21

US20190054013A1

Human necessities

LOW FREQUENCY GLATIRAMER ACETATE THERAPY

#3 | 2018-11-01

US20180311149A1

Human necessities

LOW FREQUENCY GLATIRAMER ACETATE THERAPY

#4 | 2018-07-05

US20180185274A1

Human necessities

LOW FREQUENCY GLATIRAMER ACETATE THERAPY

#5 | 2018-03-08

US20180064639A1

Human necessities

LOW FREQUENCY GLATIRAMER ACETATE THERAPY

#6 | 2017-10-19

US20170296464A1

Human necessities

LOW FREQUENCY GLATIRAMER ACETATE THERAPY

#7 | 2017-07-13

US20170196803A1

Human necessities

LOW FREQUENCY GLATIRAMER ACETATE THERAPY

#8 | 2017-04-06

US20170095523A1

Human necessities

LOW FREQUENCY GLATIRAMER ACETATE THERAPY

#9 | 2016-09-01

US20160250251A1

Human necessities

LOW FREQUENCY GLATIRAMER ACETATE THERAPY

#10 | 2016-01-28

US20160025707A1

Physics

PROCESS FOR THE MEASUREMENT OF THE POTENCY OF GLATIRAMER ACETATE

#11 | 2015-09-10

US20150250845A1

Human necessities

Low frequency glatiramer acetate therapy

#12 | 2015-07-23

US20150202247A1

Human necessities

Low frequency glatiramer acetate therapy

#13 | 2015-06-18

US20150164977A1

Human necessities

LOW FREQUENCY GLATIRAMER ACETATE THERAPY

#14 | 2015-04-02

US20150094488A1

Human necessities

PROCESS FOR THE MEASUREMENT OF THE POTENCY OF GLATIRAMER ACETATE

#15 | 2013-06-27

US20130165387A1

Human necessities

Low frequency glatiramer acetate therapy

#16 | 2013-01-24

US20130023485A1

Chemistry; metallurgy

PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMATIC LUPUS ERYTHEMATOSUS

#17 | 2012-12-06

US20120309671A1

Physics

PROCESS FOR THE MEASUREMENT OF THE POTENCY OF GLATIRAMER ACETATE

#18 | 2012-03-22

US20120071416A1

Human necessities

Low frequency glatiramer acetate therapy

#19 | 2011-08-04

US20110189706A1

Physics

Process for the measurement of the potency of glatiramer acetate

#20 | 2011-02-24

US20110046065A1

Human necessities

Low frequency glatiramer acetate therapy

#21 | 2009-07-02

US20090169559A1

Chemistry; metallurgy

Parenteral formulations of peptides for the treatment of systemic lupus erythematosus

#22 | 2009-02-26

US20090053253A1

Physics

Process for the measurement of the potency of glatiramer acetate

#23 | 2008-11-20

US20080287366A1

Human necessities

Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

#24 | 2008-09-30

US10313726

Process for the measurement of the potency of glatiramer acetate

#25 | 2007-11-13

US10758572

Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

#26 | 2007-10-18

US20070244056A1

Human necessities

Combination Therapy With Glatiramer Acetate and Riluzole

#27 | 2005-01-13

US20050008634A1

Chemistry; metallurgy

Parenteral formulations of peptides for the treatment of systemic lupus erythematosus

InventorID:

54572 ⎘